Trade Invivyd Inc. - IVVD CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023512% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.00129% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1.18 |
| Open | 1.26 |
| 1-Year Change | -68.97% |
| Day's Range | 1.26 - 1.91 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Feb 21, 2025 | 1.73 | 0.49 | 39.52% | 1.24 | 2.07 | 1.23 |
| Feb 20, 2025 | 1.18 | -0.15 | -11.28% | 1.33 | 1.37 | 1.18 |
| Feb 19, 2025 | 1.37 | -0.02 | -1.44% | 1.39 | 1.42 | 1.30 |
| Feb 18, 2025 | 1.43 | -0.07 | -4.67% | 1.50 | 1.54 | 1.31 |
| Feb 14, 2025 | 1.58 | 0.26 | 19.70% | 1.32 | 1.59 | 1.32 |
| Feb 13, 2025 | 1.34 | -0.06 | -4.29% | 1.40 | 1.43 | 1.28 |
| Feb 12, 2025 | 1.49 | -0.02 | -1.32% | 1.51 | 1.64 | 1.40 |
| Feb 11, 2025 | 1.65 | 0.29 | 21.32% | 1.36 | 1.74 | 1.24 |
| Feb 10, 2025 | 1.54 | -0.46 | -23.00% | 2.00 | 2.00 | 1.41 |
| Feb 7, 2025 | 2.01 | 0.02 | 1.01% | 1.99 | 2.61 | 1.94 |
| Feb 6, 2025 | 1.95 | -0.57 | -22.62% | 2.52 | 2.71 | 1.86 |
| Feb 5, 2025 | 2.08 | 0.94 | 82.46% | 1.14 | 2.32 | 0.96 |
| Feb 4, 2025 | 1.22 | 0.01 | 0.83% | 1.21 | 1.40 | 1.02 |
| Feb 3, 2025 | 1.03 | 0.60 | 139.53% | 0.43 | 1.08 | 0.42 |
| Jan 29, 2025 | 0.39 | -0.01 | -2.50% | 0.40 | 0.40 | 0.39 |
| Jan 28, 2025 | 0.39 | -0.01 | -2.50% | 0.40 | 0.40 | 0.39 |
| Jan 27, 2025 | 0.39 | -0.05 | -11.36% | 0.44 | 0.47 | 0.39 |
| Jan 24, 2025 | 0.44 | 0.02 | 4.76% | 0.42 | 0.45 | 0.41 |
| Jan 23, 2025 | 0.40 | 0.01 | 2.56% | 0.39 | 0.42 | 0.39 |
| Jan 21, 2025 | 0.39 | -0.01 | -2.50% | 0.40 | 0.40 | 0.39 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Invivyd Inc. Company profile
About Adagio Therapeutics Inc
Adagio Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The Company's initial focus is on the virus SARS-CoV-2, its variants and the disease caused by this virus, which is known as Coronavirus Infectious Disease (COVID-19). The Company is developing its lead product candidate, ADG20, for the treatment and prevention of coronavirus disease 2019 (COVID-19). ADG20 is designed to be a potent, long-acting and broadly neutralizing antibody for both the treatment and prevention of COVID-19 including disease caused by variants, as either a single or combination agent. The Company is also evaluating broadly neutralizing antibodies, such as ADG10, for potential use in combination with ADG20 for COVID-19.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Adagio Therapeutics Inc revenues was not reported. Net loss increased from $48.1M to $143.7M. Higher net loss reflects Research and development increase from $7.3M to $110.9M (expense), Selling, general and administrative increase from $890K to $15.5M (expense), Stock-based Compensation in SGA increase from $2K to $6.3M (expense).
| Industry: | Bio Therapeutic Drugs |
1601 Trapelo Road
Suite 178
WALTHAM
MASSACHUSETTS 02451
US
News
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025
Ripple XRP price prediction: Third-party price target
Discover the ripple (XRP) price predictions for 2025 and beyond, with analyst price targets and CFDs trading strategies on Capital.com
15:29, 6 February 2025
Apple (AAPL) stock price forecast: third-party price target
We looked at the forecasts for Apple stock in 10 years to see where the price would likely be at that point and the challenges the company could face. Read more.
11:22, 6 February 2025
FARTCOIN price prediction: Third-party price target
Read our FARTCOIN price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:18, 29 January 2025
MELANIA coin ($MELANIA) price prediction: Third party price target
Read our MELANIA crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts.
11:33, 22 January 2025
TRUMP coin ($TRUMP) price prediction: third-party price target
Read our TRUMP crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:52, 22 January 2025
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025People also watch
Still looking for a broker you can trust?
Join the 690,000+ traders worldwide that chose to trade with Capital.com